AzTrials
AzTrials

Impaired Renal FunctionOrdoclic-IRNCT00784381

Computer Prescribing System and Impaired Renal Function

An observational study of Impaired Renal Function, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of a counselling system coupled to a computer prescribing system Read more about this study

Who is it for?
Any age
Conditions the study is for
Impaired Renal Function
What is being tested?
computer-assisted counselling about target drugs
Type of treatment
Medical device
How many people
12 participants
Where
1 siteFrance
Study dates
May 2007to Dec 2008
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients hospitalized in geriatric units

Who may be able to join

  • geriatrics hospital units or nursing homes
  • using the same electronic prescribing system called ORDOCLIC
  • agreeing to participate in the study

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

France1 site
  • hopital Charles Foix et Université Paris 6

    Ivry-sur-Seine, 94 200

Other trials in France

About this study

Official title: Impact of a Counselling System Coupled With a Computer Prescribing System to Optimize the Use of the Drugs for Old Subjects Having Renal Function Impairment

To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of a counselling system coupled to a computer prescribing system

Read the detailed description

Context: The incidence of drug side effects increases with patient age, and the frail old subjects hospitalized in geriatric units are particularly exposed to this risk. Optimizing drug prescription is an important issue to prevent the side effects. Among the various possible actions, it is important to pay attention to impaired renal function which requires careful dose adjustment for drugs eliminated by renal way.

Objective: To evaluate the quality of orders for target drugs in old patients with impaired renal function, hospitalized or living in long stay units, and to improve these practices by means of counselling system coupled to a computer prescribing system. The computer prescribing system allow (a) to detect in real-time the order of drugs contraindicated in case of renal failure or prescribed in excessive amount taking into account the creatinine clearance (ClCr), and (b) to counsel the physician in these situations.

Participants: A coordinating centre (team of geriatrics 1, hospital Charles Foix, Ivry-sur-Seine, France), and 12 hospital investigator centres (hospital services of geriatrics working already in network, including the co-ordinating centre), and the department of Biostatistics (hospital Pitié-Salpétrière, Paris)

Type of study: Intervention study, cluster randomised, open, parallel.

General design: The investigator centres will be equipped with the electronic prescribing system (EPS) developed for the project. For each patient, the software requires the seizure of weight and plasma creatinine and calculates ClCr using Cockcroft formula, from which the result is accessible to the physician. After a phase of training of the EPS, the quality of the orders given to old subjects having renal failure (defined by ClCr<60 ml/mn) will be studied for 3 months under natural conditions of prescribing, without use of the counselling system (sequence A). After this phase, the counselling system will be activated for 6 months (sequence B) in 6 investigatory centres chosen by a cluster randomisation process. The centres were paired by the numbers of orders during the sequence A. For each pair, the centres were allocated to either intervention or control group by a randomisation table.

Reference frame to evaluate the quality of target drug orders:This reference frame aims to analyze the respect of the mentions of the "summaries of characteristics of products" (or RCP) relative to the impaired renal function. Drug RCP is a health authorities-approved document which describes in detail the information for prescribing. It corresponds in the US to the FDA-approved Full prescribing information. Using an automated analysis of the RCP, we will identify target drugs, defined as drugs which are contraindicated in case of renal failure or are cited in precautions for use for patient with impaired renal function. For each speciality thus identified, the possible thresholds of ClCr implied to define the counter-indication or the adjustment of dose will be sought by reading and analyzes CCP. An order line will be regarded as inappropriate if the drug is contraindicated in renal failure or if the dose prescribed exceeds that indicated in RCP for the level of patient's ClCr.

Counselling system: This system will operate in patients with ClCr <60 ml/mn. It will comprise three functionalities: (a) detection of orders of a drug contraindicated in case of renal failure and production of an alert message; (b) detection of excessive dose taking into account patient's ClCr and production of an alert message; (c) counsel to monitor plasma concentration of drugs having a renal elimination in the event of impaired renal function. This system will be very largely based on the data obtained to work out the reference frame.

Intervention: The investigator centres will be allocated to the group Intervention (6 centres) or Controls, without intervention (6 centres). The intervention applied for 6 months (sequence B), consists in activating the counselling system. An alert message indicates to the physician, according to the case, that the drug is contraindicated in the event of impaired renal function or that dose must be adjusted, by indicating the amounts recommended adjusted to ClCr when it are mentioned in the CCP. The physician keeps the final choice of his order and the prescribed dose. If the final choice differs from the counsel of the system of council the reason for the maintenance of the regulation is asked.

Data collection: Information concerning the investigator centres and the patients (type of stay, age, sex, weight, score of dependence of Activities off daily living room (ADL), index of co morbidity, plasma creatinine); occurred of adverse drug reactions and their description; lines of orders. All the data necessary for the study will be recorded through the EPS and seizures by the physician will be transmitted to the co-ordinating centre after encoding via Internet network.

Statistical analysis: The analysis will relate on the patients having ClCr lower than 60 mL/mn during the duration of the study and to the orders which are made to them. The characteristics of the patients of each group (Control/Intervention) and the proportion of target drugs will be studied and compared during the sequence A, then during the sequence B. We will compare the reductions in the proportions of inappropriate target drug orders between the sequences B and A between the Intervention group and Control (principal judgement criterion). In addition will be required in the Intervention units the existence during the 6 months of use of a possible effect of training of the physicians (progressive transfer of the expertise to the physician) which could result in a time-related reduction in the number of counsels generated by physician. Lastly, the adverse drug reactions which have occurred during the study period will be collected to analyze their nature, their incidence and their possible bonds with impaired renal function in order to guide future studies on this set of themes.

Expected results: If such a system proves to be effective to optimize prescribing of the drugs among in-patients having impaired renal function and if it is well accepted by the physicians, diffusion could be considered in centres of geriatrics. In the same way, similar studies in hospital medical wards with no geriatricians in their staff or also in family medicine settings could be considered. The algorithms will be made available for the developers which would wish to integrate it into other applications of regulations.

Being tested
computer-assisted counselling about target drugs
Keywords
Renal failure, Elderly, Drug Therapy Computer-Assisted, Quality of care, Patients With Impaired Renal Function, Inappropriateness of target drug prescribed
Medical subject headings
Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • computer-assisted counselling about target drugsDevice

    implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value

Study groups in NCT00784381
Study groupRoleWhat they receive
1Not described
Receives: Device: computer-assisted counselling about target drugs
2These units use the same electronic prescribing system, but had no counselling software
Receives: Device: computer-assisted counselling about target drugs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of the changes from baseline of proportions [patients with inappropriate target drug prescribing/patients with creatinine clearance<60 ml/mn] between control and intervention groups

    Measured: 6 months

Secondary outcomes (1)
  1. Time-related improvement of target drug prescribing in intervention units

    Measured: 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2008 (estimated)
  2. Study startMay 2007
  3. Primary completionDec 2008
  4. Study completionDec 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00784381
Sponsor's protocol ID
AOM 05118
Acronym
Ordoclic-IR
Status last verified
Oct 2008
First submitted
27 Oct 2008
Last updated
19 Nov 2012
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Impaired Renal Function, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Nov 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of the changes from baseline of proportions [patients with inappropriate target drug prescribing/patients with creatinine clearance<60 ml/mn] between control and intervention groups (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2012.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in